JP2006526031A - ヒストンデアセチラーゼ阻害物質を含む医薬組成物 - Google Patents

ヒストンデアセチラーゼ阻害物質を含む医薬組成物 Download PDF

Info

Publication number
JP2006526031A
JP2006526031A JP2006519178A JP2006519178A JP2006526031A JP 2006526031 A JP2006526031 A JP 2006526031A JP 2006519178 A JP2006519178 A JP 2006519178A JP 2006519178 A JP2006519178 A JP 2006519178A JP 2006526031 A JP2006526031 A JP 2006526031A
Authority
JP
Japan
Prior art keywords
combination according
group
component
cancer
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006519178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006526031A5 (enExample
Inventor
理 中西
達朗 菅原
秀幸 右田
康浩 松葉
Original Assignee
シエーリング アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シエーリング アクチエンゲゼルシャフト filed Critical シエーリング アクチエンゲゼルシャフト
Publication of JP2006526031A publication Critical patent/JP2006526031A/ja
Publication of JP2006526031A5 publication Critical patent/JP2006526031A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006519178A 2003-05-26 2004-05-26 ヒストンデアセチラーゼ阻害物質を含む医薬組成物 Pending JP2006526031A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26
PCT/JP2004/007562 WO2004103369A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Publications (2)

Publication Number Publication Date
JP2006526031A true JP2006526031A (ja) 2006-11-16
JP2006526031A5 JP2006526031A5 (enExample) 2006-12-28

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006519178A Pending JP2006526031A (ja) 2003-05-26 2004-05-26 ヒストンデアセチラーゼ阻害物質を含む医薬組成物

Country Status (27)

Country Link
US (1) US20070098816A1 (enExample)
EP (1) EP1626719A1 (enExample)
JP (1) JP2006526031A (enExample)
KR (1) KR100938712B1 (enExample)
CN (2) CN101322707A (enExample)
AR (1) AR045318A1 (enExample)
AU (1) AU2004241873C1 (enExample)
BR (1) BRPI0410959A (enExample)
CA (4) CA2634766A1 (enExample)
CL (1) CL2004001278A1 (enExample)
CO (1) CO5660262A2 (enExample)
CR (1) CR8163A (enExample)
CU (1) CU23490B7 (enExample)
EC (1) ECSP056253A (enExample)
IL (1) IL171941A0 (enExample)
ME (1) MEP32308A (enExample)
MX (1) MXPA05012345A (enExample)
NO (1) NO20055417L (enExample)
NZ (1) NZ543591A (enExample)
PE (1) PE20050206A1 (enExample)
RS (1) RS20050884A (enExample)
RU (1) RU2322971C2 (enExample)
TW (1) TW200505424A (enExample)
UA (1) UA81499C2 (enExample)
UY (1) UY28330A1 (enExample)
WO (1) WO2004103369A1 (enExample)
ZA (1) ZA200509515B (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008515840A (ja) * 2004-10-08 2008-05-15 インデナ エッセ ピ ア １０−デアセチル−ｎ−デベンゾイル−パクリタキセルの製造のための半合成方法
JP2010527908A (ja) * 2006-12-19 2010-08-19 サイクラセル リミテッド Ｃｎｄａｃ（２’−シアノ−２’−デオキシ−ｎ４−パルミトイル−１−ベータ−ｄ−アラビノフラノシル−シトシン）及び細胞毒性薬を含む組合せ
JP2012500819A (ja) * 2008-08-29 2012-01-12 バイエル ファーマ アクチエンゲゼルシャフト Ｎ‐（２‐アミノフェニル）‐４‐［ｎ‐（ピリジン‐３‐イル）‐メトキシカルボニル‐アミノメチル］‐ベンズアミド（ｍｓ‐２７５）結晶多形ｂ
JP2012529435A (ja) * 2009-06-08 2012-11-22 ギリアード サイエンシーズ， インコーポレイテッド アルカノイルアミノベンズアミドアニリンｈｄａｃインヒビター化合物
JP2014139181A (ja) * 2006-12-26 2014-07-31 Pharma Cyclics Inc 併用療法においてヒストンデアセチラーゼ阻害剤を使用し、バイオマーカーをモニタする方法
JP2014528423A (ja) * 2011-09-30 2014-10-27 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒ阻害剤による膵臓癌及び非小細胞肺癌の治療
US9492423B2 (en) 2011-09-13 2016-11-15 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
CA2540108A1 (en) * 2003-09-25 2005-04-07 Astellas Pharma Inc. Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
KR20080003334A (ko) * 2005-03-11 2008-01-07 더 리젠트스 오브 더 유니버시티 오브 콜로라도 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
WO2006122319A2 (en) 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
JP5409015B2 (ja) 2006-02-14 2014-02-05 プレジデント アンド フェロウズ オブ ハーバード カレッジ ヒストンデアセチラーゼ阻害剤
AU2007248656B2 (en) 2006-05-03 2013-04-04 Dana-Farber Cancer Institute, Inc. Histone deacetylase and tubulin deacetylase inhibitors
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
US8293513B2 (en) * 2007-12-14 2012-10-23 Georgetown University Histone deacetylase inhibitors
US8440716B2 (en) 2008-07-23 2013-05-14 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
BRPI0924084B1 (pt) 2008-12-19 2021-12-21 Vertex Pharmaceuticals Incorporated Derivados de pirazina e composição farmacêutica que os compreende
EP2395972A4 (en) * 2009-02-11 2014-02-12 Liangping Yu PARTICULATE COMPOSITION AND METHOD FOR PRODUCING THE SAME
EP2424516A4 (en) * 2009-05-01 2014-04-02 Oncozyme Pharma Inc PENTAMIDINE COMBINATIONS FOR THE TREATMENT OF CANCER
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
JP2013503174A (ja) * 2009-08-25 2013-01-31 アブラクシス バイオサイエンス， エルエルシー タキサンおよびヘッジホッグ阻害剤のナノ粒子組成物を使用する併用療法
AU2011253025A1 (en) 2010-05-12 2012-11-29 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SG10201606774UA (en) 2011-09-30 2016-10-28 Vertex Pharma Processes for making compounds useful as inhibitors of atr kinase
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
US20140044802A1 (en) 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US9738637B2 (en) 2013-03-12 2017-08-22 Celgene Quantical Research, Inc. Histone demethylase inhibitors
WO2014141129A2 (en) * 2013-03-14 2014-09-18 Grueneberg Dorre A Novel methods, compounds, and compositions for inhibition of ros
EA201592012A8 (ru) * 2014-02-21 2018-10-31 Общество С Ограниченной Ответственностью "Биолаб 612" Применение флагеллина для улучшенной химиотерапии
EA201790604A1 (ru) 2014-09-17 2017-09-29 Селджен Квонтисел Рисёрч, Инк. Ингибиторы гистондеметилазы
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics
WO2025041160A1 (en) * 2023-08-19 2025-02-27 Birla Institute Of Technology And Science (Bits), Pilani Bifunctional conjugate molecules for cancer treatment and process of making the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10152462A (ja) * 1996-09-30 1998-06-09 Mitsui Chem Inc 分化誘導剤
WO2002085400A1 (en) * 2001-04-24 2002-10-31 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of dna methylation and histone deacetylase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
YU22401A (sh) * 1998-09-25 2004-03-12 Warner-Lambert Company Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom
EP1177796B1 (en) * 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Medicament for prevention or therapeutic treatment of liver disease
NZ518668A (en) * 1999-11-10 2004-04-30 Warner Lambert Co Combination chemotherapy comprising acetyldinaline and paclitaxal and/or carboplatin
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10152462A (ja) * 1996-09-30 1998-06-09 Mitsui Chem Inc 分化誘導剤
WO2002085400A1 (en) * 2001-04-24 2002-10-31 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of dna methylation and histone deacetylase

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008515840A (ja) * 2004-10-08 2008-05-15 インデナ エッセ ピ ア １０−デアセチル−ｎ−デベンゾイル−パクリタキセルの製造のための半合成方法
JP2012136544A (ja) * 2004-10-08 2012-07-19 Indena Spa ドセタキセルの製造方法及び医薬
JP2010527908A (ja) * 2006-12-19 2010-08-19 サイクラセル リミテッド Ｃｎｄａｃ（２’−シアノ−２’−デオキシ−ｎ４−パルミトイル−１−ベータ−ｄ−アラビノフラノシル−シトシン）及び細胞毒性薬を含む組合せ
JP2014139181A (ja) * 2006-12-26 2014-07-31 Pharma Cyclics Inc 併用療法においてヒストンデアセチラーゼ阻害剤を使用し、バイオマーカーをモニタする方法
US9408816B2 (en) 2006-12-26 2016-08-09 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
JP2012500819A (ja) * 2008-08-29 2012-01-12 バイエル ファーマ アクチエンゲゼルシャフト Ｎ‐（２‐アミノフェニル）‐４‐［ｎ‐（ピリジン‐３‐イル）‐メトキシカルボニル‐アミノメチル］‐ベンズアミド（ｍｓ‐２７５）結晶多形ｂ
JP2012529435A (ja) * 2009-06-08 2012-11-22 ギリアード サイエンシーズ， インコーポレイテッド アルカノイルアミノベンズアミドアニリンｈｄａｃインヒビター化合物
US9492423B2 (en) 2011-09-13 2016-11-15 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
JP2014528423A (ja) * 2011-09-30 2014-10-27 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒ阻害剤による膵臓癌及び非小細胞肺癌の治療
JP2017119724A (ja) * 2011-09-30 2017-07-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒ阻害剤による膵臓癌及び非小細胞肺癌の治療
US10813929B2 (en) 2011-09-30 2020-10-27 Vertex Pharmaceuticals Incorporated Treating cancer with ATR inhibitors
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Also Published As

Publication number Publication date
ZA200509515B (en) 2006-07-26
RU2005140570A (ru) 2006-06-10
NO20055417L (no) 2005-12-19
RU2322971C2 (ru) 2008-04-27
AU2004241873C1 (en) 2009-01-22
BRPI0410959A (pt) 2006-07-04
US20070098816A1 (en) 2007-05-03
MXPA05012345A (es) 2006-02-08
MEP32308A (en) 2010-10-10
ECSP056253A (es) 2006-10-25
NZ543591A (en) 2009-09-25
CU23490B7 (es) 2010-02-23
AR045318A1 (es) 2005-10-26
PE20050206A1 (es) 2005-03-26
NO20055417D0 (no) 2005-11-16
CA2634765A1 (en) 2004-12-02
CA2527191A1 (en) 2004-12-02
RS20050884A (sr) 2008-04-04
IL171941A0 (en) 2006-04-10
AU2004241873B2 (en) 2008-05-08
CN101322707A (zh) 2008-12-17
CR8163A (es) 2006-07-14
KR100938712B1 (ko) 2010-01-25
AU2004241873A1 (en) 2004-12-02
CA2634766A1 (en) 2004-12-02
CA2634709A1 (en) 2004-12-02
CO5660262A2 (es) 2006-07-31
AU2004241873B8 (en) 2008-05-29
TW200505424A (en) 2005-02-16
KR20060009371A (ko) 2006-01-31
WO2004103369A1 (en) 2004-12-02
UA81499C2 (en) 2008-01-10
CN1794991A (zh) 2006-06-28
CL2004001278A1 (es) 2005-05-06
UY28330A1 (es) 2004-12-31
EP1626719A1 (en) 2006-02-22

Similar Documents

Publication Publication Date Title
KR100938712B1 (ko) 히스톤 데아세틸라제 저해 물질을 함유하는 의약 조성물
KR101673731B1 (ko) 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법
EP2786753B1 (en) Combination therapy with an antitumor antibiotic
KR101848131B1 (ko) 저용량 이리노테칸염산염 수화물을 함유하는 항종양제
JP2009538317A (ja) 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
JP2024538117A (ja) Ｗｅｅ１阻害剤と抗ｃｄ４７抗体との組み合わせ。
WO2010086964A1 (ja) がん治療のための併用療法
KR101401220B1 (ko) 방사선 치료 증강제
KR101924801B1 (ko) 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
SA04250273B1 (ar) تركيبة صيدلانية تحتوي على مثبط إنزيم الهستوت دي أسيتيليز
TW201716064A (zh) 供治療癌症之口服投予紫杉醇及Ｐ－ｇｐ抑制劑的治療性組合
US20090281105A1 (en) Radiotherapy enhancer
MX2023011814A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o la mejora del cancer.
CN112089710B (zh) 4-羟基异亮氨酸在制备抗肿瘤药物中的应用
WO2015102380A1 (ko) 신규한 8-옥소프로토베르베린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 nfat5의 활성 관련 질환의 예방 또는 치료용 약학적 조성물
KR101847252B1 (ko) 이리노테칸염산염 수화물을 함유하는 항종양제
EP2117539B1 (en) A method of administering an antitumor compound
WO2020045461A1 (ja) ピラゾロ［３，４－ｄ］ピリミジン化合物を有効成分とする治療剤
KR101656394B1 (ko) 신규한 8-옥소프로토베르베린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 nfat5의 활성 관련 질환의 예방 또는 치료용 약학적 조성물
CN112716949A (zh) 一类抗肿瘤药物组合物、制剂和应用
JPH03133913A (ja) 新規美白剤
Adjei et al. 26 ORAL Phase Ib and pharmacodynamic study of the MEK inhibitor AZD6244 (ARRY-142886) in patients with advanced solid malignancies
HK1202421B (en) Combination therapy with an antitumor antibiotic

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100803

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110104